Stifel Terminates Coverage On Oncolytics Biotech Due To Reallocation Of Resources

In a report published Monday, Stifel analyst Brian Klein terminated coverage on

. In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward." Oncolytics Biotech closed on Friday at $0.42.